Michael Murray

List of Publications by Year
in descending order

106	3,133	126907	182427
papers	citations	33 h-index	51 g-index

107	107	107	3230
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The aryl-ureido fatty acid CTU activates endoplasmic reticulum stress and PERK/NOXA-mediated apoptosis in tumor cells by a dual mitochondrial-targeting mechanism. Cancer Letters, 2022, 526, 131-141.	7.2	5
2	Compritol solid lipid nanoparticle formulations enhance the protective effect of betulinic acid derivatives in human MÃ¼ller cells against oxidative injury. Experimental Eye Research, 2022, 215, 108906.	2.6	9
3	The unfolded protein response and the biology of uveal melanoma. Biochimie, 2022, 197, 9-18.	2.6	1
4	The application of natural compounds in uveal melanoma drug discovery. Journal of Pharmacy and Pharmacology, 2022, 74, 660-680.	2.4	2
5	Preclinical Evaluation of Ixabepilone in Combination with VEGF Receptor and PARP Inhibitors in Taxane-Sensitive and Taxane-Resistant MDA-MB-231 Breast Cancer Cells. Journal of Pharmaceutical Sciences, 2022, , .	3.3	0
6	The multi-kinase inhibitor afatinib serves as a novel candidate for the treatment of human uveal melanoma. Cellular Oncology (Dordrecht), 2022, 45, 601-619.	4.4	1
7	Impaired Transport Activity of Human Organic Anion Transporters (OATs) and Organic Anion Transporting Polypeptides (OATPs) by Wnt Inhibitors. Journal of Pharmaceutical Sciences, 2021, 110, 914-924.	3.3	5
8	The Potential Application of Pentacyclic Triterpenoids in the Prevention and Treatment of Retinal Diseases. Planta Medica, 2021, 87, 511-527.	1.3	8
9	Differential inhibition of human CYP2C8 and molecular docking interactions elicited by sorafenib and its major N-oxide metabolite. Chemico-Biological Interactions, 2021, 338, 109401.	4.0	4
10	Development of new therapeutic options for the treatment of uveal melanoma. FEBS Journal, 2021, 288, 6226-6249.	4.7	19
11	Procyanidin B2 and rutin in Ginkgo biloba extracts protect human retinal pigment epithelial (RPE) cells from oxidative stress by modulating Nrf2 and Erk1/2 signalling. Experimental Eye Research, 2021, 207, 108586.	2.6	20
12	PTU, a novel ureido-fatty acid, inhibits MDA-MB-231 cell invasion and dissemination by modulating Wnt5a secretion and cytoskeletal signaling. Biochemical Pharmacology, 2021, 192, 114726.	4.4	0
13	Carbon Chain Length Modulates MDAâ€MBâ€231 Breast Cancer Cell Killing Mechanisms by Mitochondrially Targeted Arylâ^'Urea Fatty Acids. ChemMedChem, 2020, 15, 247-255.	3.2	2
14	The involvement of human organic anion transporting polypeptides (OATPs) in drug-herb/food interactions. Chinese Medicine, 2020, 15, 71.	4.0	21
15	Aryl urea substituted fatty acids: a new class of protonophoric mitochondrial uncoupler that utilises a synthetic anion transporter. Chemical Science, 2020, 11, 12677-12685.	7.4	14
16	Omega-3 Polyunsaturated Fatty Acid Derived Lipid Mediators and their Application in Drug Discovery. Current Medicinal Chemistry, 2020, 27, 1670-1689.	2.4	5
17	Betulinic acid derivatives can protect human MÃ¼ller cells from glutamate-induced oxidative stress. Experimental Cell Research, 2019, 383, 111509.	2.6	11
18	Inhibition of Hepatic CYP2D6 by the Active N-Oxide Metabolite of Sorafenib. AAPS Journal, 2019, 21, 107.	4.4	2

#	Article	IF	Citations
19	Simvastatin protects photoreceptors from oxidative stress induced by allâ€•trans â€•retinal, through the upâ€•regulation of interphotoreceptor retinoid binding protein. British Journal of Pharmacology, 2019, 176, 2063-2078.	5.4	10
20	Aryl-urea fatty acids that activate the p38 MAP kinase and down-regulate multiple cyclins decrease the viability of MDA-MB-231 breast cancer cells. European Journal of Pharmaceutical Sciences, 2019, 129, 87-98.	4.0	5
21	Sorafenib N-Oxide Is an Inhibitor of Human Hepatic CYP3A4. AAPS Journal, 2019, 21, 15.	4.4	10
22	Carboxylate Analogues of Arylâ€Ureaâ€Substituted Fatty Acids That Target the Mitochondria in MDAâ€MBâ€231 Breast Cancer Cells to Promote Cell Death. ChemMedChem, 2018, 13, 1036-1043.	3.2	4
23	Differential effects of hepatic cirrhosis on the intrinsic clearances of sorafenib and imatinib by CYPs in human liver. European Journal of Pharmaceutical Sciences, 2018, 114, 55-63.	4.0	10
24	Variation in the Response of Clozapine Biotransformation Pathways in Human Hepatic Microsomes to CYP1A2â€•and CYP3A4â€•selective Inhibitors. Basic and Clinical Pharmacology and Toxicology, 2018, 122, 388-395.	2.5	11
25	The 5â€²-AMP-Activated Protein Kinase Regulates the Function and Expression of Human Organic Anion Transporting Polypeptide 1A2. Molecular Pharmacology, 2018, 94, 1412-1420.	2.3	7
26	Nanoemulsion-Enabled Oral Delivery of Novel Anticancer Ï‰-3 Fatty Acid Derivatives. Nanomaterials, 2018, 8, 825.	4.1	20
27	Recent advance in the pharmacogenomics of human Solute Carrier Transporters (SLCs) in drug disposition. Advanced Drug Delivery Reviews, 2017, 116, 21-36.	13.7	61
28	Trafficking and other regulatory mechanisms for organic anion transporting polypeptides and organic anion transporters that modulate cellular drug and xenobiotic influx and that are dysregulated in disease. British Journal of Pharmacology, 2017, 174, 1908-1924.	5.4	44
29	A Novel Arylurea Fatty Acid That Targets the Mitochondrion and Depletes Cardiolipin To Promote Killing of Breast Cancer Cells. Journal of Medicinal Chemistry, 2017, 60, 8661-8666.	6.4	17
30	Activation of ALDH1A1 in MDA-MB-468 breast cancer cells that over-express CYP2J2 protects against paclitaxel-dependent cell death mediated by reactive oxygen species. Biochemical Pharmacology, 2017, 143, 79-89.	4.4	29
31	A novel synthetic analogue of Ï‰â€3 17,18â€•epoxyeicosatetraenoic acid activates TNF receptorâ€1/ASK1/JNK signaling to promote apoptosis in human breast cancer cells. FASEB Journal, 2017, 31, 5246-5257.	0.5	29
32	The Role of N-Glycosylation in Maintaining the Transporter Activity and Expression of Human Oligopeptide Transporter 1. Molecular Pharmaceutics, 2016, 13, 3449-3456.	4.6	5
33	Activation of the pro-migratory bone morphogenetic protein receptor 1B gene in human MDA-MB-468 triple-negative breast cancer cells that over-express CYP2J2. International Journal of Biochemistry and Cell Biology, 2016, 80, 173-178.	2.8	10
34	CYP2J2 â€“ regulation, function and polymorphism. Drug Metabolism Reviews, 2016, 48, 351-368.	3.6	29
35	Casein Kinase 2 Is a Novel Regulator of the Human Organic Anion Transporting Polypeptide 1A2 (OATP1A2) Trafficking. Molecular Pharmaceutics, 2016, 13, 144-154.	4.6	10
36	Putative Transmembrane Domain 6 of the Human Organic Anion Transporting Polypeptide 1A2 (OATP1A2) Influences Transporter Substrate Binding, Protein Trafficking, and Quality Control. Molecular Pharmaceutics, 2015, 12, 111-119.	4.6	20

#	Article	IF	Citations
37	Anti-tumor activities of lipids and lipid analogues and their development as potential anticancer drugs. , 2015, 150, 109-128.		61
38	Pro-migratory actions of the prostacyclin receptor in human breast cancer cells that over-express cyclooxygenase-2. Biochemical Pharmacology, 2015, 96, 306-314.	4.4	9
39	Liquid Chromatography-Tandem Mass Spectrometry Assay Suitable for Quantifying Omega-3 Epoxy-Fatty Acid Analogs in Mouse Brain and Plasma. Journal of Liquid Chromatography and Related Technologies, 2015, 38, 891-897.	1.0	1
40	Prostanoids regulate angiogenesis acting primarily on IP and EP4 receptors. Microvascular Research, 2015, 101, 127-134.	2.5	14
41	Cytochrome P450-Mediated Biotransformation of Sorafenib and Its N-Oxide Metabolite: Implications for Cell Viability and Human Toxicity. Chemical Research in Toxicology, 2015, 28, 92-102.	3.3	20
42	Kava dermopathy in Fiji: an acquired ichthyosis?. International Journal of Dermatology, 2014, 53, 1490-1494.	1.0	11
43	Lipid analogues as potential drugs for the regulation of mitochondrial cell death. British Journal of Pharmacology, 2014, 171, 2051-2066.	5.4	12
44	Ï‰-3 Polyunsaturated fatty acids and their metabolites as inhibitors of mammalian tumorigenesis. Phytochemistry Reviews, 2014, 13, 139-156.	6.5	14
45	Selective Inhibition of Human Solute Carrier Transporters by Multikinase Inhibitors. Drug Metabolism and Disposition, 2014, 42, 1851-1857.	3.3	55
46	Synthetic Ï‰-3 Epoxyfatty Acids As Antiproliferative and Pro-apoptotic Agents in Human Breast Cancer Cells. Journal of Medicinal Chemistry, 2014, 57, 7459-7464.	6.4	33
47	The multikinase inhibitor axitinib is a potent inhibitor of human CYP1A2. Biochemical Pharmacology, 2014, 88, 245-252.	4.4	10
48	PDZK1 and NHERF1 Regulate the Function of Human Organic Anion Transporting Polypeptide 1A2 (OATP1A2) by Modulating Its Subcellular Trafficking and Stability. PLoS ONE, 2014, 9, e94712.	2.5	24
49	Functional Analysis of Novel Polymorphisms in the Human SLCO1A2 Gene that Encodes the Transporter OATP1A2. AAPS Journal, 2013, 15, 1099-1108.	4.4	41
50	Antiproliferative and Antimigratory Actions of Synthetic Long Chain n-3 Monounsaturated Fatty Acids in Breast Cancer Cells That Overexpress Cyclooxygenase-2. Journal of Medicinal Chemistry, 2012, 55, 7163-7172.	6.4	28
51	Synthesis of unsymmetrical biaryl ureas from N-carbamoylimidazoles: kineticsÂand application. Tetrahedron, 2012, 68, 6065-6070.	1.9	23
52	Toxicological Actions of Plant-Derived and Anthropogenic Methylenedioxyphenyl-Substituted Chemicals in Mammals and Insects. Journal of Toxicology and Environmental Health - Part B: Critical Reviews, 2012, 15, 365-395.	6.5	17
53	Role of human CYP3A4 in the biotransformation of sorafenib to its major oxidized metabolites. Biochemical Pharmacology, 2012, 84, 215-223.	4.4	50
54	Inhibition of hepatic microsomal monooxygenase activity by cinchocaine: mechanistic studies and effects of ionization. Journal of Pharmacy and Pharmacology, 2011, 38, 472-475.	2.4	1

#	Article	IF	Citations
55	The Ï‰â€3 epoxide of eicosapentaenoic acid inhibits endothelial cell proliferation by p38 MAP kinase activation and cyclin D1/CDK4 downâ€regulation. British Journal of Pharmacology, 2011, 162, 1143-1155.	5.4	50
56	Protein kinase C regulates the internalization and function of the human organic anion transporting polypeptide 1A2. British Journal of Pharmacology, 2011, 162, 1380-1388.	5.4	41
57	Roles of Mitogen-Activated Protein Kinases in the Regulation of CYP Genes. Current Drug Metabolism, 2010, 11, 850-858.	1.2	7
58	The Participation of Cytochrome P450 3A4 in Clozapine Biotransformation Is Detected in People With Schizophrenia by High-Throughput In Vivo Phenotyping. Journal of Clinical Psychopharmacology, 2010, 30, 629-631.	1.4	6
59	Role of CYP pharmacogenetics and drug-drug interactions in the efficacy and safety of atypical and other antipsychotic agentsâ€. Journal of Pharmacy and Pharmacology, 2010, 58, 871-885.	2.4	95
60	Facile and Stereoselective Synthesis of (Z)-15-Octadecenoic Acid and (Z)-16-Nonadecenoic Acid: Monounsaturated Omega-3 Fatty Acids. Lipids, 2010, 45, 159-165.	1.7	6
61	Functional characterization of nonsynonymous single nucleotide polymorphisms in the human organic anion transporter 4 (hOAT4). British Journal of Pharmacology, 2010, 159, 419-427.	5.4	34
62	Impaired transactivation of the human CYP2J2 arachidonic acid epoxygenase gene in HepG2 cells subjected to nitrative stress. British Journal of Pharmacology, 2010, 159, 1440-1449.	5.4	19
63	Participation of CYP2C8 and CYP3A4 in the Nâ€demethylation of imatinib in human hepatic microsomes. British Journal of Pharmacology, 2010, 161, 1059-1069.	5.4	73
64	Impaired irinotecan biotransformation in hepatic microsomal fractions from patients with chronic liver disease. British Journal of Clinical Pharmacology, 2010, 70, 400-408.	2.4	11
65	Cytochromes P450: Roles in the Biotransformation of Chemicals in Cigarette Smoke and Impact of Smoking Cessation on Concurrent Drug Therapy. Journal of Smoking Cessation, 2010, 5, 107-114.	1.0	1
66	Up-Regulation of Human CYP2J2 in HepG2 Cells by Butylated Hydroxyanisole Is Mediated by c-Jun and Nrf2. Molecular Pharmacology, 2010, 77, 987-994.	2.3	26
67	Pharmacogenetics of Phase I and Phase II Drug Metabolism. Current Pharmaceutical Design, 2010, 16, 204-219.	1.9	94
68	Influence of Genetic Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Sulfonylurea Drugs. Current Drug Metabolism, 2009, 10, 643-658.	1.2	44
69	A High-Throughput Assay Using Liquid Chromatography-Tandem Mass Spectrometry for Simultaneous In Vivo Phenotyping of 5 Major Cytochrome P450 Enzymes in Patients. Therapeutic Drug Monitoring, 2009, 31, 239-246.	2.0	34
70	A liquid chromatography/electrospray ionization mass spectrometry (LCâ€“MS/MS) assay for the determination of irinotecan (CPT-11) and its two major metabolites in human liver microsomal incubations and human plasma samples. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2008, 875, 522-530.	2.3	42
71	Interindividual Variation in Relative CYP1A2/3A4 Phenotype Influences Susceptibility of Clozapine Oxidation to Cytochrome P450-Specific Inhibition in Human Hepatic Microsomes. Drug Metabolism and Disposition, 2008, 36, 2547-2555.	3.3	30
72	Modulation of angiogenesis by Ï‰-3 polyunsaturated fatty acids is mediated by cyclooxygenases. Blood, 2008, 111, 3514-3521.	1.4	113

#	Article	IF	Citations
73	CYP-Mediated Clozapine Interactions: How Predictable Are They?. Current Drug Metabolism, 2007, 8, 307-313.	1.2	49
74	Impaired Microsomal Oxidation of the Atypical Antipsychotic Agent Clozapine in Hepatic Steatosis. Journal of Pharmacology and Experimental Therapeutics, 2007, 322, 770-777.	2.5	37
75	Role of signalling systems in the effects of dietary factors on the expression of mammalian CYPs. Expert Opinion on Drug Metabolism and Toxicology, 2007, 3, 185-196.	3.3	13
76	Altered CYP Expression and Function in Response to Dietary Factors: Potential Roles in Disease Pathogenesis. Current Drug Metabolism, 2006, 7, 67-81.	1.2	134
77	Cytochromes P450: decision-making tools for personalized therapeutics. Current Opinion in Molecular Therapeutics, 2006, 8, 480-6.	2.8	6
78	Characterization of a c-Jun-responsive module in the 5â€²-flank of the human CYP2J2 gene that regulates transactivation. Biochemical Journal, 2005, 391, 631-640.	3.7	21
79	Pretranslational upregulation of microsomal CYP4A in rat liver by intake of a high-sucrose, lipid-devoid diet containing orotic acid. Biochemical Pharmacology, 2005, 69, 709-717.	4.4	17
80	Phospho-STAT5 accumulation in nuclear fractions from vitamin A-deficient rat liver. FEBS Letters, 2005, 579, 3669-3673.	2.8	9
81	Role of activator protein-1 in the down-regulation of the human CYP2J2 gene in hypoxia. Biochemical Journal, 2003, 373, 669-680.	3.7	46
82	Mechanisms of Inhibitory and Regulatory Effects of Methylenedioxyphenyl Compounds on Cytochrome P450-Dependent Drug Oxidation. Current Drug Metabolism, 2000, 1, 67-84.	1.2	144
83	DRUG-MEDIATED INACTIVATION OF CYTOCHROME P450. Clinical and Experimental Pharmacology and Physiology, 1997, 24, 465-470.	1.9	59
84	Restoration of cytochrome P450 2C11 in vitamin Aâ€deficient rat liver by exogenous androgen. FASEB Journal, 1996, 10, 1058-1063.	0.5	12
85	All-trans -retinoic acid 4-hydroxylation in human liver microsomes: in vitro modulation by therapeuticretinoids. British Journal of Clinical Pharmacology, 1996, 41, 609-612.	2.4	5
86	Differential alterations of cytochrome P450 proteins in livers from patients with severe chronic liver disease. Hepatology, 1995, 21, 120-128.	7.3	192
87	Downregulation of male-specific cytochrome P450s 2C11 and 3A2 in bile ductâ€“ligated male rats: Importance to reduced hepatic content of cytochrome P450 in cholestasis. Hepatology, 1995, 22, 580-587.	7.3	37
88	Pretranslational down-regulation of cytochromes P450 2C11 and 3A2 in male rat liver by tumor necrosis factor Î±. Gastroenterology, 1995, 109, 198-205.	1.3	55
89	Selectivity and sensitivity of changes in serum bile acids during induction of cirrhosis in ratsselectivity and sensitivity of changes in serum bile acids during induction of cirrhosis in rats. Hepatology, 1993, 18, 1224-1231.	7.3	14
90	Participation of a cytochrome P450 enzyme from the 2C subfamily in progesterone 21-hydroxylation in sheep liver. Journal of Steroid Biochemistry and Molecular Biology, 1992, 43, 591-593.	2.5	29

#	Article	IF	Citations
91	P450 Enzymes. Clinical Pharmacokinetics, 1992, 23, 132-146.	3.5	157
92	Inhibition and metabolite complexation of rat hepatic microsomal cytochrome p450 by tricyclic antidepressants. Biochemical Pharmacology, 1992, 43, 2065-2071.	4.4	30
93	Increased expression of cytochrome P450 IIIA2 in male rat liver after dietary vitamin A supplementation. Archives of Biochemistry and Biophysics, 1991, 286, 618-624.	3.0	37
94	In vitro and in vivo studies of the effect of vitamin E on microsomal cytochrome P450 in rat liver. Biochemical Pharmacology, 1991, 42, 2107-2114.	4.4	38
95	Human cytochrome P450 isoforms. Gastroenterology, 1990, 99, 885-889.	1.3	35
96	Effect of genetic obesity and experimental diabetes on hepatic microsomal mixed function oxidase activities. Journal of Gastroenterology and Hepatology (Australia), 1990, 5, 256-263.	2.8	19
97	Complexation of cytochrome P-450 isozymes in hepatic microsomes from SKF 525-A-induced rats. Archives of Biochemistry and Biophysics, 1988, 262, 381-388.	3.0	41
98	Impaired androgen 16Î±-hydroxylation in hepatic microsomes from carbon tetrachloride-cirrhotic male rats. Gastroenterology, 1987, 93, 141-147.	1.3	46
99	Methylenedioxyphenyl complexes with microsomal cytochrome P-450: In vivo complex formation in rat liver and in midgut tissues of the Southern armyworm (Spodoptera eridania). Pesticide Biochemistry and Physiology, 1987, 28, 140-147.	3.6	7
100	Mechanisms of the Inhibition of Cytochrome P 450-Mediated Drug Oxidation by Therapeutic Agents. Drug Metabolism Reviews, 1987, 18, 55-81.	3.6	83
101	Different effects of short- and long-term dietary choline-deficiency on hepatic microsomal phospholipids and drug oxidation. Journal of Gastroenterology and Hepatology (Australia), 1987, 2, 27-33.	2.8	1
102	Selective reactivation of steroid hydroxylases following dissociation of the isosafrole metabolite complex with rat hepatic cytochrome P-450. Archives of Biochemistry and Biophysics, 1986, 251, 471-478.	3.0	28
103	Methylenedioxyphenyl compounds as inducers of cytochrome P-450 and monooxygenase activity in the southern armyworm (Spodoptera eridania) and the rat. Pesticide Biochemistry and Physiology, 1986, 26, 310-322.	3.6	16
104	Quantitative Structure-Activity Relationships in the Displacement of the Dihydrosafrole Metabolite-Cytochrome P-450 Complex. QSAR and Combinatorial Science, 1985, 4, 18-22.	1.2	4
105	In vitro effects of quinoline derivatives on cytochrome p-450 and aminopyrine n-demethylase activity in rat hepatic microsomes. Biochemical Pharmacology, 1984, 33, 3277-3281.	4.4	46
106	Effects of dihydrosafrole on cytochromes P-450 and drug oxidation in hepatic microsomes from control and induced rats. Toxicology and Applied Pharmacology, 1983, 68, 66-76.	2.8	56